Frank Lichtenberg
Courtney C. Brown Professor of Business at Columbia Business School
Biography
Columbia Business School
Biography
Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.
Mr. Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organizations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.
He was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research!America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.
He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organizations. He has served as a consultant to private organizations and government agencies including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council. He is an affiliate of the economics consulting firm Analysis Group.
Teaching
Spring 2018
Economics of Healthcare and Pharmaceuticals (MBA)
Managerial Economics (EMBA)
Summer 2017
Managerial Economics Continued (EMBA)
Economics of Healthcare and Pharmaceuticals (EMBA)
Spring 2017
Managerial Economics (EMBA)
Economics of Healthcare and Pharmaceuticals (MBA)
Summer 2016
Economics of Healthcare and Pharmaceuticals (EMBA)
Spring 2016
Economics of Healthcare and Pharmaceuticals (MBA)
Managerial Economics (EMBA)
Summer 2015
Economics of Healthcare and Pharmaceuticals (MBA)
Economics of Healthcare and Pharmaceuticals (EMBA)
Spring 2015
Economics of Healthcare and Pharmaceuticals (MBA)
Fall 2014
Economics of Healthcare and Pharmaceuticals (EMBA)
Summer 2014
Economics of Healthcare and Pharmaceuticals (EMBA)
Economics of Healthcare and Pharmaceuticals (MBA)
Spring 2014
Economics of Healthcare and Pharmaceuticals (EMBA)
Economics of Healthcare and Pharmaceuticals (MBA)
Fall 2013
Economics of Healthcare and Pharmaceuticals (EMBA)
Spring 2013
Economics of Health Care & Pharmaceuticals (MBA)
Fall 2012
Managerial Economics (1.5 cr) (EMBA)
Economics of Healthcare & Pharmaceuticals (EMBA)
Columbia Caseworks cases
Can Health Technology Assessment Help Control Drug Costs? (2016)
Coauthor(s): Frank Lichtenberg
More Information
Research
Journal articles
The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001–2007 In PharmacoEconomics (2012)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Has Pharmaceutical Innovation Reduced Social Security Disability Growth? In International Journal of the Economics of Business (2011)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Despite steep costs, payments for new cancer drugs make economic sense In Nature Medicine (2011)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The quality of medical care, behavioral risk factors, and longevity growth In International Journal of Health Care Finance and Economics (2011)
Coauthor(s): Frank Lichtenberg
More Information
What Are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation? In Health Affairs (2011)
Coauthor(s): Frank Lichtenberg, Bhaven Sampat
More Information
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia In Forum for Health Economics & Policy (2010)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Pharmaceutical innovation and mortality in the United States, 1960–2000. A commentary on Schnittker and Karandinos In Social Science and Medicine (2010)
Coauthor(s): Frank Lichtenberg
More Information
Pharmaceutical Price Discrimination and Social Welfare In Capitalism and Society (2010)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The effect of drug vintage on survival: Micro evidence from Puerto Rico''s Medicaid program In Advances in health economics and health services research (2010)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Availability of New Drugs and Americans'' Ability to Work In Journal of Occupational and Environmental Medicine (2005)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001 In International Journal of Health Care Finance and Economics (2005)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Effects of Medicare on Health Care Utilization and Outcomes In Frontiers in Health Policy Research (2002)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Do (More and Better) Drugs Keep People Out of Hospitals? In American Economic Review (1996)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Private R and D Investment Response to Federal Design and Technical Competitions In American Economic Review (1988)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Comparative Advantage of Educated Workers in Implementing New Technology In Review of Economics and Statistics (1987)
Coauthor(s): Ann Bartel, Frank Lichtenberg
More Information Download paper (PDF)
Books
Corporate Takeovers and Productivity (1992)
Coauthor(s): Frank Lichtenberg
More Information
Chapters
Pharmaceutical Knowledge-Capital Accumulation and Longevity In Measuring Capital in the New Economy (2005)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Web-only articles
Importation and Innovation In Chazen Web Journal of International Business (2005)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries In Chazen Web Journal of International Business (2005)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Working papers
The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data In Working Paper No. 19593 (2013)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Impact of New (Orphan) Drug Approvals on Premature Mortality from Rare Diseases in the U.S. and France, 1999–2007 (2011)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Has medical innovation reduced cancer mortality? In Working Paper No. 15880 (2010)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Is Home Health Care a Substitute for Hospital Care? (2010)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The impact of medical knowledge accumulation and diffusion on health: Evidence from Medline and other N.I.H. data (2010)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth In NBER Working Papers, Working Paper 15068 (2009)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
Benefits and Costs of Newer Drugs: An Update (2005)
Coauthor(s): Frank Lichtenberg
More Information
Pharmaceutical-Embodied Technical Progress, Longevity, and Quality of Life: Drugs as ''Equipment for Your Health'' (2005)
Coauthor(s): Frank Lichtenberg, Suchin Virabhak
More Information
Sources of U.S. Longevity Increase, 1960-1997 (2005)
Coauthor(s): Frank Lichtenberg
More Information
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry (2005)
Coauthor(s): Frank Lichtenberg
More Information
The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output (2005)
Coauthor(s): Frank Lichtenberg
More Information
The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs? (2005)
Coauthor(s): Adriana Lleras-Muney, Frank Lichtenberg
More Information
The Expanding Pharmaceutical Arsenal in the War on Cancer In NBR Working Paper 10328 (2005)
Coauthor(s): Frank Lichtenberg
More Information Download paper (PDF)
The Impact of New Drug Launches on Longevity: From 52 Countries, 1982-2001 (2005)
Coauthor(s): Frank Lichtenberg
More Information
The Effect of New Drugs on Mortality from Rare Diseases and HIV In NBER Working Paper 8677 (2002)
Coauthor(s): Frank Lichtenberg
More Information
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey In NBER Working Paper 8147 (2001)
Coauthor(s): Frank Lichtenberg
More Information
Pharmaceutical Innovation, Mortality Reduction, and Economic Growth In NBER Working Paper W6569 (1998)
Coauthor(s): Frank Lichtenberg
More Information
The Allocation of Publicly-Funded Biomedical Research In NBER Working Paper 6601 (1998)
Coauthor(s): Frank Lichtenberg
More Information
The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality In NBER Working Paper No. W5418 (1996)
Coauthor(s): Frank Lichtenberg
More Information
Ideas and Insights
Even at Current Prices, Drug Innovation Is a Cost-Effective Means to Curb Cancer (2016)
Awards And Honors
2010 Garfield Economic Impact Award
For the publication "The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978 - 2004
2003 Milken Institute Award for Distinguished Economic Research
For the paper "Pharmaceutical knowledge-capital accumulation and longevity"
Winner of the 1998 Schumpeter Prize
For the paper "Pharmaceutical innovation as a process of creative destruction"
Videos
Frank Lichtenberg
Read about executive education
Other experts
Nik Nanos
Nik Nanos is a Canadian public opinion pollster and an expert on image research and crisis communications management. In 1987 Nanos founded SES Research while he was a student at Queen's University. The company is now known as Nanos Research, a market and public opinion research firm with clients...
Mark Fritz
Mark Fritz is an international leadership speaker & consultant focused on helping international business leaders to achieve even greater success in leading across distances & cultures. He has lived & worked across the world and speaks regularly on the Power of Ownership in leading tod...
Velina Collins
Velina Collins has extensive & broad-based Human Resource Management (HRM) consulting & training experience with a diverse clientele which includes government & private and profit & non-profit organizations and local, multi-nationals & public listed companies. She is also a ce...
Looking for an expert?
Contact us and we'll find the best option for you.